Tag Archives: NASDAQ:LGND

What Did This CEO Just Do with Personal Shares of Ligand Pharma (NASDAQ: LGND)?

Today, the CEO of Ligand Pharma (NASDAQ: LGND), John L. Higgins, sold shares of LGND for $903.9K. Following John L. Higgins’ last LGND Sell transaction on November 20, 2017, the stock climbed by 127.1%. In addition to John L. Higgins,

The EVP,Finance & Strategy and CFO of Ligand Pharma is Exercising Options

Yesterday it was reported that the EVP,Finance & Strategy and CFO of Ligand Pharma (NASDAQ: LGND), Matthew Korenberg, exercised options to sell 18,357 LGND shares at $85.79 a share, for a total transaction value of $4.71M. Following Matthew Korenberg’s last

Stephens Believes Ligand Pharma (NASDAQ: LGND) Still Has Room to Grow

In a report released yesterday, Drew Jones from Stephens reiterated a Buy rating on Ligand Pharma (NASDAQ: LGND), with a price target of $248. The company’s shares closed yesterday at $247.02, close to its 52-week high of $254.24. According to

Analysts Are Bullish on These Healthcare Stocks: LGND, CARA

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (NASDAQ: LGND), Cara Therapeutics (NASDAQ: CARA) and Keryx Biopharma (NASDAQ: KERX) with bullish sentiments. Ligand Pharma (LGND) H.C. Wainwright analyst

H.C. Wainwright Sticks to Its Buy Rating for Ligand Pharma

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Ligand Pharma (NASDAQ: LGND), with a price target of $182. The company’s shares closed yesterday at $157.28. According to TipRanks.com, Pantginis has 0 stars on

H.C. Wainwright Maintains Their Buy Rating on Ligand Pharma

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Ligand Pharma (NASDAQ: LGND) today and set a price target of $170. The company’s shares closed yesterday at $159.81, close to its 52-week high of $170.30. Pantginis wrote: “Kyprolis Beats;